Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Mar. 31, 2021

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Weighted Average, March 31, 2021			Range, March 31, 2021			Weighted Average, March 31, 2020			Range, March 31, 2020
Volatility		65	%	58%	-	65%		68	%	68%	-	70%
Dividend yield		-			—			—			—
Risk-free interest rate		0.79	%	0.47%	-	0.82%		1.75%		1.74%	-	1.75%
Expected term (years)		5.8		5.0	to	5.9		5.0		5.0	to	5.2

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at July 1, 2020		9,511,600	$	0.74		4.5	$	-
Granted		960,000		1.10
Exercised		-		-
Forfeited		-		-
Expired		-		-
Outstanding at March 31, 2021		10,471,600	$	0.77		3.9	$	10,252,975
Exercisable at March 31, 2021		10,471,600	$	0.77		3.9	$	10,252,975

Schedule of Nonvested Share Activity [Table Text Block]

	Options			Weighted Average Grant-Date Fair Value
Nonvested at July 1, 2020		-		$	-
Granted		960,000			1.06
Vested		(960,000	)		(1.06	)
Nonvested at March 31, 2021		—		$	—

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three months ended March 31, 2021		Three months ended March 31, 2020		Nine months ended March 31, 2021		Nine months ended March 31, 2020
General and administrative:
Change in fair value from modification of option terms	$	-	$	-	$	8,775	$	-
Change in fair value from modification of warrant terms		-		-		25,506		-
Fair value of stock options expensed		816,050		-		816,050		92,000
Total	$	816,050	$	-	$	850,331	$	92,000
Research and development:
Fair value of stock options expensed	$	201,650	$	-	$	201,650	$	7,500
Total	$	201,650	$	-	$	201,650	$	7,500